- Global Pharma News & Resources

Plant-Based Vaccines Market To Find Better Growth with US$ 1.8 Billion Threshold By 2026 | CAGR: 11.7%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Plant-based Vaccines Marketby Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), By Source (Tobacco Plant, Maize, Potato, and Others), By Application (Influenza, Zika Virus Disease, Ebola Virus Disease, Poultry Diseases, and Others), and by Region (North America, and Europe) is estimated to be valued at US$ 927.0 million in 2020, and is projected to exhibit a CAGR of 11.7% over the forecast period (2020 – 2026).

Get FREE Sample PDF Including COVID-19 Impact Analysis:

Various studies are being conducted on plant-based vaccines as a cheap alternative to the conventional vaccine in terms of efficiency, production time, and immune system. The market players, and rising number of start-ups and research institutes are focused on R&D activities to develop treatment therapies for various infectious disease indications such as flu, dengue, norovirus, and avian influenza H5N1; based on new plant-based source vaccine. For instance, in August 2018, researchers from Arizona State University’s (ASU) Biodesign Institute developed a norovirus vaccine from tobacco plant. Genetic engineering allowed researchers to transfer specific genes from tobacco plant in designing plant-based vaccine for norovirus. Plant-based vaccine is safe and effective for use against various infectious diseases, as it activates patient’s immune system. In June 2018, researchers from the University of Nottingham, Malaysia, announced a project to develop plant-based vaccine for treatment of dengue fever caused by Aedes genus mosquitoes.

By using tobacco plant, researchers were successful in producing vaccine antigen that has the capability to neutralize dengue virus. Moreover, vaccines produced through plant sources provide a new platform to produce vaccines that can be orally administered rather than intravenously, which is the route of administration for most of the currently available vaccines. Researchers are also conducting research on edible plant species such as lettuce for production of vaccines in the near future. Successful completion of research studies are expected to help in developing safe and cost effective treatment to prevent dengue. For instance, according to the Journal of Botany: March 2016, the dengue virus vaccine targeting dengue-3 serotype polyprotein (DENV3prM/E) was produced in Lactuca sativa (lettuce) through a chloroplast transformation. It is further concluded that lettuce is an excellent host for agroinfiltration with deconstructed viral vectors.

Browse 20 Market Data Tables and 14 Figures spread through 128 Pages and in-depth TOC on ‘Global Plant-based Vaccines Market, by Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), By Source (Tobacco Plant, Maize, Potato, and Others), By Application (Influenza, Zika Virus Disease, Ebola Virus Disease, Poultry Diseases, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026’

To know the latest trends and insights prevalent in the plant-based vaccines market press release, click the link below:

Major players operating in the global plant-based vaccines market are adopting inorganic growth strategies such as collaboration and acquisition to expand their R&D capabilities in development of new plant-based vaccines. For instance, in June 2016, The Texas A&M University System (including Texas A & M University AgriLife Research and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) entered into an agreement with iBio, Inc. and its subsidiary, iBio CMO LLC, for a collaborative program in plant-produced pharmaceuticals. This collaboration is expected to leverage R&D resources of the research institute with the commercial therapeutics and vaccine development, and manufacturing capabilities of iBio. Through this collaboration, their objective was to rapidly develop and test cost-effective, commercial, therapeutic, and vaccine solutions against various diseases such as influenza and Ebola. Furthermore, in July 2013, Medicago, Inc., a Canada-based biopharmaceutical company, entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation, whereby Medicago was acquired by Mitsubishi with 60% share in Medicago, Inc. 40% of the shares are currently held by Philip Morris Investments B.V.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @

Key Takeaways of the Global Plant-based Vaccines Market:

  • The global plant-based vaccines market is expected to exhibit a CAGR of 11.7% over the forecast period. This is attributed to rising number of R&D activities by key players to develop plant-based vaccines through novel sources.
  • Among vaccine type, viral vaccines segment is expected to hold largest share in the market over the forecast period. Plant-based viral vaccines have been studied against Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), influenza virus, Bluetongue Virus (BTV), and rabies virus.
  • Among source, the tobacco plant segment is expected to hold largest market share in 2020 and is expected to retain its dominance over the forecast period. In the manufacturing of plant-based vaccines, tobacco plant is mostly the preferred plant source. It is also being studied to develop vaccines for the treatment of diseases such as norovirus, Zika virus, polio, and influenza.
  • Among application, the influenza segment is expected to hold largest market revenue and market share during the forecast period (2020-2026). Among influenza patients, plant-based vaccine is largely used in patients suffering from seasonal influenza. The infection caused due to influenza can be significantly reduced by using plant-based vaccines.
  • Major players operating in the global plant-based vaccines market include Medicago, Inc., iBio, Inc., and Icon Genetics- GmbH

Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 23-Sep-2020